Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Weinreich, W. Frishman (2014)
Antihyperlipidemic Therapies Targeting PCSK9Cardiology in Review, 22
Jennifer Robinson, B. Nedergaard, W. Rogers, J. Fialkow, J. Neutel, David Ramstad, R. Somaratne, J. Legg, Patric Nelson, R. Scott, S. Wasserman, R. Weiss (2014)
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.JAMA, 311 18
J. Tice, Dhruv Kazi, S. Pearson (2016)
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.JAMA internal medicine, 176 1
M. Sabatine, R. Giugliano, A. Keech, Narimon Honarpour, S. Wiviott, S. Murphy, J. Kuder, Huei Wang, Thomas Liu, S. Wasserman, P. Sever, T. Pedersen (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseThe New England Journal of Medicine, 376
P. Jellinger, Y. Handelsman, P. Rosenblit, Z. Bloomgarden, V. Fonseca, A. Garber, G. Grunberger, Chris Guerin, D. Bell, J. Mechanick, Rachel Pessah-Pollack, K. Wyne, Donald Smith, E. Brinton, S. Fazio, Michael Davidson (2017)
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 23 Suppl 2
Jennifer Robinson, M. Farnier, M. Krempf, J. Bergeron, G. Luc, M. Averna, E. Stroes, G. Langslet, F. Raal, M. Shahawy, M. Koren, N. Lepor, C. Lorenzato, R. Pordy, U. Chaudhari, J. Kastelein (2015)
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.The New England journal of medicine, 372 16
N. Stone, Jennifer Robinson, A. Lichtenstein, C. Noel, B. Merz, D. Lloyd‐Jones, C. Blum, P. Mcbride, R. Eckel, F. Schwartz, A. Goldberg, Susan Shero, Rn, D. Gordon, Sidney Smith, D. Levy, K. Watson, P. Wilson, Karen Eddleman, N. Jarrett, K. Labresh, Lev Nevo, J. Wnek, Jeffrey Anderson, J. Halperin, N. Albert, J. Hochman, B. Bozkurt, R. Kovacs, R. Brindis, Macc Ohman, L. Curtis, S. Pressler, D. DeMets, F. Sellke, R. Guyton, W. Shen, G. Tomaselli, Stone Nj, Robinson J, Lichtenstein Ah, M. Bairey, Blum Cn, Eckel Cb, Goldberg Rh, Gordon Ac, Levy D, Lloyd-Jones Dm, P. Mcbride, Js Schwartz, Shero St, Smith Sc, W. Wilson (2014)
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.Circulation, 129 25 Suppl 2
S. Nicholls, R. Puri, T. Anderson, C. Ballantyne, L. Cho, J. Kastelein, W. Koenig, R. Somaratne, H. Kassahun, Jingyuan Yang, S. Wasserman, R. Scott, I. Ungi, J. Podolec, A. Ophuis, J. Cornel, Marilyn Borgman, D. Brennan, S. Nissen (2016)
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.JAMA, 316 22
L. Joseph, Jennifer Robinson (2015)
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.Progress in cardiovascular diseases, 58 1
ABSTRACT PCSK9 inhibitors are a novel medical therapy for treating hypercholesterolemia. This article reviews the basic properties of PCSK9 inhibitors, including their mechanism of action, indications, contraindications, adverse reactions, and efficacy.
Journal of the American Academy of PAs – Wolters Kluwer Health
Published: Jun 1, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.